Please enable JavaScript to continue using this application.

Compare $ANIK vs $LXEO | Chartloom

Compare

$ANIK vs $LXEO

Anika Therapeutics Inc · Lexeo Therapeutics Inc

ANIK

Anika Therapeutics Inc

LXEO

Lexeo Therapeutics Inc

Compare $ANIK vs $LXEO

Comparing Anika Therapeutics Inc and Lexeo Therapeutics Inc

ANIKAnika Therapeutics Inc

LXEOLexeo Therapeutics Inc

ANIKAnika Therapeutics Inc

Market cap

$262M

P/E (TTM)

—

Forward P/E (NTM)

57.30x

Forward P/S (NTM)

2.09x

Rev growth (TTM)

-2.5%

YTD performance

109.4%

52W performance

111.9%

FCF yield

0.2%

LXEOLexeo Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-66.4%

52W performance

-59.8%

FCF yield

-35.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ANIK

LXEO

Detailed metrics comparison

ANIK

Anika Therapeutics Inc

LXEO

Lexeo Therapeutics Inc

Market Cap

ANIK$262M

LXEO$254M

Enterprise Value

ANIK$224M

LXEO$161M

Price

ANIK$19.58

LXEO$3.23

P/E Ratio

ANIKN/A

LXEON/A

P/S Ratio

ANIK2.17x

LXEO535.16x

EV/Sales

ANIK1.85x

LXEO0.00x

EV/EBITDA

ANIK84.97x

LXEO0.00x

P/B Ratio

ANIK1.86x

LXEO1.23x

P/FCF Ratio

ANIK466.16x

LXEON/A

EV/FCF

ANIK397.81x

LXEO-1.82x

PEG Ratio

ANIKN/A

LXEON/A

Forward P/E (NTM)

ANIK57.30x

LXEON/A

Forward P/S (NTM)

ANIK2.09x

LXEON/A

Revenue (TTM)

ANIK$121M

LXEO$0

Revenue Growth (YoY)

ANIK-2.5%

LXEON/A

Forward Rev Growth

ANIK5.2%

LXEO466.0%

Gross Margin (TTM)

ANIK62.2%

LXEO0.0%

Operating Margin (TTM)

ANIK0.0%

LXEO0.0%

EBITDA Margin (TTM)

ANIK2.2%

LXEO0.0%

Net Margin (TTM)

ANIK-3.1%

LXEO0.0%

FCF Margin (TTM)

ANIK0.5%

LXEON/A

Net Income (TTM)

ANIK$-4M

LXEO$-87M

FCF (TTM)

ANIK$562K

LXEO$-89M

EPS (TTM)

ANIK-$0.28

LXEO-$1.02

ROE (TTM)

ANIK-270.0%

LXEO-4185.0%

ROA (TTM)

ANIK-204.0%

LXEO-3803.0%

ROIC (TTM)

ANIK-270.0%

LXEO-4169.0%

Cash

ANIK$38M

LXEO$93M

Debt

ANIK$0

LXEO$584K

Net Cash/Debt

ANIK$38M

LXEO$92M

Current Ratio (TTM)

ANIK4.48x

LXEO13.89x

Quick Ratio (TTM)

ANIK3.05x

LXEO13.49x

Debt/Equity (TTM)

ANIK0.00x

LXEO0.00x

Debt/Assets (TTM)

ANIK0.0%

LXEO0.0%

Interest Coverage (TTM)

ANIKN/A

LXEON/A

Net Debt/EBITDA (TTM)

ANIK0.00x

LXEO0.00x

Beta

ANIK0.23

LXEO1.62

52W Performance

ANIK111.9%

LXEO-59.8%

YTD Performance

ANIK109.4%

LXEO-66.4%

% from 52W High

ANIK-14.4%

LXEO-70.6%

% from 52W Low

ANIK125.8%

LXEO8.4%

Asset Turnover (TTM)

ANIK0.65x

LXEO0.00x

FCF Yield (TTM)

ANIK0.2%

LXEO-35.0%

Earnings Yield (TTM)

ANIK-1.4%

LXEO-34.4%

Dividend Yield (TTM)

ANIKN/A

LXEON/A

Rule of 40

ANIK-2.0

LXEO0.0

EV/GP/RG

ANIK0.81

LXEON/A

Ticker research

View ANIK research View LXEO research

Metric	ANIK Anika Therapeutics Inc	LXEO Lexeo Therapeutics Inc
Market & Valuation
Market Cap	$262M	$254M
Enterprise Value	$224M	$161M
Price	$19.58	$3.23
P/E Ratio	N/A	N/A
P/S Ratio	2.17x	535.16x
EV/Sales	1.85x	0.00x
EV/EBITDA	84.97x	0.00x
P/B Ratio	1.86x	1.23x
P/FCF Ratio	466.16x	N/A
EV/FCF	397.81x	-1.82x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	57.30x	N/A
Forward P/S (NTM)	2.09x	N/A
Revenue & Growth
Revenue (TTM)	$121M	$0
Revenue Growth (YoY)	-2.5%	N/A
Forward Rev Growth	5.2%	466.0%
Profitability
Gross Margin (TTM)	62.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	2.2%	0.0%
Net Margin (TTM)	-3.1%	0.0%
FCF Margin (TTM)	0.5%	N/A
Net Income (TTM)	$-4M	$-87M
FCF (TTM)	$562K	$-89M
EPS (TTM)	-$0.28	-$1.02
ROE (TTM)	-270.0%	-4185.0%
ROA (TTM)	-204.0%	-3803.0%
ROIC (TTM)	-270.0%	-4169.0%
Financial Health
Cash	$38M	$93M
Debt	$0	$584K
Net Cash/Debt	$38M	$92M
Current Ratio (TTM)	4.48x	13.89x
Quick Ratio (TTM)	3.05x	13.49x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.23	1.62
52W Performance	111.9%	-59.8%
YTD Performance	109.4%	-66.4%
% from 52W High	-14.4%	-70.6%
% from 52W Low	125.8%	8.4%
Efficiency & Yields
Asset Turnover (TTM)	0.65x	0.00x
FCF Yield (TTM)	0.2%	-35.0%
Earnings Yield (TTM)	-1.4%	-34.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2.0	0.0
EV/GP/RG	0.81	N/A
Ticker research	View ANIK research	View LXEO research

Valuation

P/S Ratio

ANIK

2.17x

LXEO

535.16x

EV/FCF

LXEO

-1.82x

ANIK

397.81x

Growth & revenue

Revenue Growth TTM

ANIK

-2.5%

Forward Revenue Growth

LXEO

466.0%

ANIK

5.2%

Profitability & performance

Gross Margin

ANIK

62.2%

LXEO

0.0%

ROE

ANIK

-270.0%

LXEO

-4185.0%

FCF Yield %

ANIK

0.2%

LXEO

-35.0%

52-Week Performance

ANIK

111.9%

LXEO

-59.8%

Detailed metrics comparison

ANIK

Anika Therapeutics Inc

LXEO

Lexeo Therapeutics Inc

Market Cap

ANIK$262M

LXEO$254M

Enterprise Value

ANIK$224M

LXEO$161M

Price

ANIK$19.58

LXEO$3.23

P/E Ratio

ANIKN/A

LXEON/A

P/S Ratio

ANIK2.17x

LXEO535.16x

EV/Sales

ANIK1.85x

LXEO0.00x

EV/EBITDA

ANIK84.97x

LXEO0.00x

P/B Ratio

ANIK1.86x

LXEO1.23x

P/FCF Ratio

ANIK466.16x

LXEON/A

EV/FCF

ANIK397.81x

LXEO-1.82x

PEG Ratio

ANIKN/A

LXEON/A

Forward P/E (NTM)

ANIK57.30x

LXEON/A

Forward P/S (NTM)

ANIK2.09x

LXEON/A

Revenue (TTM)

ANIK$121M

LXEO$0

Revenue Growth (YoY)

ANIK-2.5%

LXEON/A

Forward Rev Growth

ANIK5.2%

LXEO466.0%

Gross Margin (TTM)

ANIK62.2%

LXEO0.0%

Operating Margin (TTM)

ANIK0.0%

LXEO0.0%

EBITDA Margin (TTM)

ANIK2.2%

LXEO0.0%

Net Margin (TTM)

ANIK-3.1%

LXEO0.0%

FCF Margin (TTM)

ANIK0.5%

LXEON/A

Net Income (TTM)

ANIK$-4M

LXEO$-87M

FCF (TTM)

ANIK$562K

LXEO$-89M

EPS (TTM)

ANIK-$0.28

LXEO-$1.02

ROE (TTM)

ANIK-270.0%

LXEO-4185.0%

ROA (TTM)

ANIK-204.0%

LXEO-3803.0%

ROIC (TTM)

ANIK-270.0%

LXEO-4169.0%

Cash

ANIK$38M

LXEO$93M

Debt

ANIK$0

LXEO$584K

Net Cash/Debt

ANIK$38M

LXEO$92M

Current Ratio (TTM)

ANIK4.48x

LXEO13.89x

Quick Ratio (TTM)

ANIK3.05x

LXEO13.49x

Debt/Equity (TTM)

ANIK0.00x

LXEO0.00x

Debt/Assets (TTM)

ANIK0.0%

LXEO0.0%

Interest Coverage (TTM)

ANIKN/A

LXEON/A

Net Debt/EBITDA (TTM)

ANIK0.00x

LXEO0.00x

Beta

ANIK0.23

LXEO1.62

52W Performance

ANIK111.9%

LXEO-59.8%

YTD Performance

ANIK109.4%

LXEO-66.4%

% from 52W High

ANIK-14.4%

LXEO-70.6%

% from 52W Low

ANIK125.8%

LXEO8.4%

Asset Turnover (TTM)

ANIK0.65x

LXEO0.00x

FCF Yield (TTM)

ANIK0.2%

LXEO-35.0%

Earnings Yield (TTM)

ANIK-1.4%

LXEO-34.4%

Dividend Yield (TTM)

ANIKN/A

LXEON/A

Rule of 40

ANIK-2.0

LXEO0.0

EV/GP/RG

ANIK0.81

LXEON/A

Ticker research

View ANIK research View LXEO research

Metric	ANIK Anika Therapeutics Inc	LXEO Lexeo Therapeutics Inc
Market & Valuation
Market Cap	$262M	$254M
Enterprise Value	$224M	$161M
Price	$19.58	$3.23
P/E Ratio	N/A	N/A
P/S Ratio	2.17x	535.16x
EV/Sales	1.85x	0.00x
EV/EBITDA	84.97x	0.00x
P/B Ratio	1.86x	1.23x
P/FCF Ratio	466.16x	N/A
EV/FCF	397.81x	-1.82x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	57.30x	N/A
Forward P/S (NTM)	2.09x	N/A
Revenue & Growth
Revenue (TTM)	$121M	$0
Revenue Growth (YoY)	-2.5%	N/A
Forward Rev Growth	5.2%	466.0%
Profitability
Gross Margin (TTM)	62.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	2.2%	0.0%
Net Margin (TTM)	-3.1%	0.0%
FCF Margin (TTM)	0.5%	N/A
Net Income (TTM)	$-4M	$-87M
FCF (TTM)	$562K	$-89M
EPS (TTM)	-$0.28	-$1.02
ROE (TTM)	-270.0%	-4185.0%
ROA (TTM)	-204.0%	-3803.0%
ROIC (TTM)	-270.0%	-4169.0%
Financial Health
Cash	$38M	$93M
Debt	$0	$584K
Net Cash/Debt	$38M	$92M
Current Ratio (TTM)	4.48x	13.89x
Quick Ratio (TTM)	3.05x	13.49x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.23	1.62
52W Performance	111.9%	-59.8%
YTD Performance	109.4%	-66.4%
% from 52W High	-14.4%	-70.6%
% from 52W Low	125.8%	8.4%
Efficiency & Yields
Asset Turnover (TTM)	0.65x	0.00x
FCF Yield (TTM)	0.2%	-35.0%
Earnings Yield (TTM)	-1.4%	-34.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2.0	0.0
EV/GP/RG	0.81	N/A
Ticker research	View ANIK research	View LXEO research